Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc (NASDAQ: GALT) pioneers novel carbohydrate-based therapies targeting galectin-3 proteins to address fibrotic diseases and cancers. This page serves as the definitive source for verified company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Investors and researchers will discover timely updates on adaptive clinical programs for conditions like MASH cirrhosis, oncology developments, and scientific advancements in galectin inhibition technology. All content is curated to provide actionable insights without speculative commentary.
The repository includes earnings reports, FDA communications, research collaborations, and therapeutic pipeline progress. Bookmark this page for streamlined access to GALT's latest developments in carbohydrate-based drug innovation and fibrotic disease research.
Galectin Therapeutics (NASDAQ: GALT) reported financial results for Q2 2024 and provided a business update. Key highlights include:
1. The NAVIGATE Phase 2b/3 trial of belapectin for MASH cirrhosis is on track for interim top-line analysis in December 2024.
2. Presented data at EASL 2024 showing no correlation between collagen content in liver biopsies and portal pressure in MASH cirrhotic patients.
3. As of June 30, 2024, the company had $25.6 million in cash and cash equivalents, with an additional $10 million available under a line of credit.
4. Q2 2024 net loss was $12.4 million ($0.20 per share), compared to $9.2 million ($0.15 per share) in Q2 2023.
5. Research and development expenses increased to $9.8 million in Q2 2024 from $7.4 million in Q2 2023.
Galectin Therapeutics (NASDAQ: GALT) has appointed Dr. Khurram Jamil as Chief Medical Officer, effective immediately. Dr. Jamil, who joined the company in March 2024 as VP of Clinical Development and Medical Director, brings over 20 years of experience in hepatology and drug development. He will lead the management of the NAVIGATE clinical trial for belapectin, a potential treatment for MASH cirrhosis.
The company expects interim top-line data from the Phase 2b portion of the NAVIGATE trial in December 2024. This trial is evaluating belapectin's efficacy in preventing esophageal varices in patients with cirrhosis due to MASH. The study has randomized 357 patients across 14 countries on five continents.
Galectin Therapeutics (NASDAQ:GALT) announced its participation in the European Association for the Study of the Liver (EASL) 2024 Congress, held June 5-8 in Milan, Italy. The company will present data from its belapectin program, highlighting the lack of correlation between collagen content in liver biopsies and portal pressure in MASH cirrhotic patients. Chief Medical Officer Pol Boudes emphasized the importance of using endoscopies to detect esophageal varices caused by increased portal pressure, rather than relying on liver biopsies. The presentation, titled 'Evaluating the correlation between portal pressure, collagen proportional area, and α-smooth muscle actin in patients with portal hypertension due to MASH cirrhosis,' will be available for EASL attendees and later on Galectin's website.
Galectin Therapeutics (NASDAQ: GALT) reported its Q1 2024 financial results and provided a business update. The NAVIGATE Phase 2b/3 trial of belapectin in liver cirrhosis due to MASH continues as planned, with an interim top-line readout expected late Q4 2024 after a positive fifth DSMB meeting.
Q1 financials show $23.6M in cash with an additional $10M available from a new line of credit. R&D expenses decreased to $8.1M from $8.8M YoY, while G&A expenses increased slightly to $1.6M from $1.5M. The net loss remained constant at $11.5M or ($0.19) per share YoY.
Corporate updates include the appointment of Dr. Khurram Jamil as VP of Clinical Development. The company mourns the loss of Dr. Stephen A. Harrison, a key figure in the belapectin program.
Galectin Therapeutics Inc. (NASDAQ: GALT) will participate in the H.C. Wainwright BioConnect Conference, presenting at the fireside chat on May 20, 2024, at 4:00 PM ET at the Nasdaq World Headquarters in New York City. The management team will be available for one-on-one meetings, and a webcast link will be provided on the Company's website.
